

PHARMACY POLICY STATEMENT

Indiana Medicaid

transplant (HSCT), or

DRUG NAME	Rezurock (belumosudil)	at least half of patient
BILLING CODE	Must use valid NDC	regarding optimal 2
BENEFIT TYPE	Pharmacy	

2nd line therapy but describe a variety of options.

Rezurock is the first rho-associated, coiled-coil kinase 2 (ROCK) inhibitor. The ROCK pathway modulates inflammatory response and fibrotic processes. ROCK inhibition is thought to both restore immune homeostasis and reduce fibrotic processes, which makes Rezurock unique from other pharmacologic treatment options. Approval was based on the phase 2 ROCKstar study.

Rezurock (belumosudil) will be considered for coverage when the following criteria are met:

Chronic Graft-Versus-Host Disease (cGVHD)

For **initial** authorization:

1. Member is at least 12 years of age; AND
2. Medication must be prescribed by or in consultation with a transplant or hematology/oncology specialist; AND
3. Member has a diagnosis of cGVHD with persistent manifestations; AND
4. Member has failed at least 2 prior lines of systemic therapy, i.e., systemic corticosteroids.

For **reauthorization**:

1. Chart notes must show improvement of signs and symptoms of disease in at least 1 organ/site, without progression in any other organ/site.

If all the above requirements are met, the medication will be approved for an additional 12 months.

